Propanc Advances PRP After Strong Preclinical Pancreatic Cancer Results

Melbourne, Australia – August 27, 2026

Propanc Reports Strong PRP Activity in Pancreatic Cancer Models

In orthotopic and patient-derived xenograft (PDX) models of advanced PDAC, intravenously administered PRP three times weekly produced more than 90% mean tumor growth inhibition compared with vehicle controls, with statistical significance reported at p < 0.001. Treatment also resulted in marked reductions in metastatic burden in the liver and peritoneum, two clinically important sites of disease dissemination. The company reported significant remodeling of the tumor microenvironment, including reduced cancer-associated fibroblast activity and fibrosis, together with suppression of EMT-associated markers. These findings are relevant because the tumor microenvironment and EMT are associated with tumor progression, invasion and treatment resistance. PRP also increased the sensitivity of chemotherapy-resistant PDAC cells to gemcitabine/nab-paclitaxel, supporting the potential for combination treatment and potentially lower chemotherapy exposure. Treated animals experienced a median overall survival extension of more than 2.5-fold compared with controls, building on previously reported data showing more than 85% tumor growth inhibition.

PRP Uses a Differentiation-Based Mechanism

PRP is a proprietary fixed-ratio combination of trypsinogen and chymotrypsinogen, two pancreatic proenzymes that Propanc is developing as a non-cytotoxic cancer therapy. The company’s proposed mechanism differs from approaches that directly inhibit oncogenic signaling pathways. Propanc states that PRP promotes differentiation of malignant cells toward a more normal phenotype, reverses EMT, targets cancer stem cells, suppresses metastasis and angiogenesis, and remodels the tumor microenvironment. The company highlighted this mechanism as potentially complementary to targeted approaches such as RAS(ON) inhibition, particularly because RAS mutations are present in a large majority of pancreatic cancers. However, the current evidence for PRP remains primarily preclinical, and the reported activity in animal models cannot yet be assumed to translate into comparable clinical benefit in humans. The potential differentiation-based mechanism therefore remains an important hypothesis that will need validation through clinical development.

Propanc Prepares PRP for Phase 1b Clinical Development

Propanc is now progressing GMP manufacturing, pharmacokinetic assay validation and clinical partnerships to support a planned Phase 1b First-in-Human study of PRP in advanced solid tumors. The planned study is expected to enroll approximately 40–45 patients, with pancreatic cancer identified as a key focus indication. The company expects to submit a clinical trial application in the coming months. PRP has also received FDA Orphan Drug Designation for pancreatic cancer, supporting its development in this rare and highly aggressive cancer setting. The next major value-driving milestones will therefore be the regulatory submission, initiation of clinical testing and initial human safety and pharmacokinetic data. While the new preclinical results are substantial, PRP has not yet demonstrated clinical efficacy in a controlled human trial, making the transition from animal models to patients the critical next step in determining whether the reported antitumor and survival effects can be reproduced clinically.

Source:Propanc Biopharma,,press relese